OUR INVESTMENT IN LANGAWARE – THE MACHINE LEARNING AND LANGUAGE BIOMARKERS SOLUTION FOR NEURODEGENERATIVE PATHOLOGIES DETECTION

OUR INVESTMENT IN LANGAWARE – THE MACHINE LEARNING AND LANGUAGE BIOMARKERS SOLUTION FOR NEURODEGENERATIVE PATHOLOGIES DETECTION

  • Posted by Metavallon VC Team
  • On July 22, 2020

We are excited to announce our latest Seed investment into healthtech startup LangAware, which provides a solution of early cognitive assessment to prevent Alzheimer’s and related Dementias.

Founded by Vassiliki Rentoumi, associate researcher in the field of Natural Language Processing and Computational Linguistics at SKEL of NCSR “Demokritos”, LangAware employs Artificial Intelligence to predict neurodegenerative diseases such as Alzheimer’s by detecting and monitoring digital biomarkers based on language and speech. This LangAware platform solution is aimed at various clinical settings, including primary healthcare, as a quick screening tool to identify people with high risk to develop Alzheimer’s or other neurodegenerative diseases. The platform’s high sensitivity and specificity can lead to larger numbers of patients being identified earlier, thus stratified and treated more effectively. The technology behind the platform has been the product of many years of research and has been battle-tested in a number of clinical environments. The Alzheimer’s disease market is expected to exceed EUR 6.5bn  in value by the end of 2026.

LangAware’s solution supports practitioners through a simple, quick and engaging decision support making tool, which includes precise state-of-the-art speech processing. The team comprises experts from various fields including software and machine learning engineers, computational linguists, data scientists, neurologists and neurolinguists. The existing round of funding will go to reinforce the team and ensure the successful deployment of secured and new pilots with partners and clients. 

LangaAware’s CEO Vassiliki Rentoumi states “The battle with dementia requires all our might. For this we have developed a “virtual expert” that helps in the early diagnosis and monitoring of the disease aiming to give patients a better quality of life. Our solution provides the primary care physicians with an accurate tool for diagnosis, the pharmaceutical companies with a more efficient patient recruitment tool for their clinical trials, and eventually the patients with remote assessment and monitoring from the comfort of their homestead”

Alexandra Choli, Partner at Metavallon VC, states “In LangAware we find both a remarkable investee and the inspiration of how technology and entrepreneurs may build towards a better life for the people around us. We are excited about the problem tackled, about the defensible intellectual property of the solution, and about the huge market it may serve, an indication of value both for our investors and for the multitude of patients that stand to benefit.”

Metavallon VC is active in Seed investments such as the one in LangAware, with rolling investment proposal submissions around the year. The firm is also active in Pre-Seed investments evaluated upon periodic cut-off dates, with the next one coming up on July 25, 2020. Interested companies are invited to readily submit their PreSeed and Seed investment proposals.

Metavallon VC is active in Seed investments such as the one in LangAware, with rolling investment proposal submissions around the year. The firm is also active in Pre-Seed investments evaluated upon periodic cut-off dates, with the next one coming up on July 25th, 2020. Interested companies are invited to readily submit  their PreSeed and Seed investment proposals at http://bit.ly/MVCStartupForm.

 3